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PaediatricsBackground: Rotavirus is a common cause of severe gastroenteritis in young children in Hong Kong (HK)
with a high economic burden. This study aimed to evaluate the cost-effectiveness of introducing rotavirus
vaccination into the HK Government’s Childhood Immunisation Programme (CIP) and to include the
potential protective effect of the vaccine against seizures.
Methods: A decision-support model was customised to estimate the potential impact, cost-effectiveness
and benefit-risk of rotavirus vaccination in children below 5 years over the period 2020–2029 in HK. Two
doses of Rotarix and three doses of RotaTeq were each compared to no vaccination. Rotavirus treatment
costs were calculated from a governmental health sector perspective (i.e., costs of public sector treat-
ment) and an overall health sector perspective (both governmental and patient, i.e., costs of public sector
treatment, private sector treatment, transport and diapers). We ran probabilistic and deterministic uncer-
tainty analyses.
Results: Introduction of rotavirus vaccination in HK could prevent 49,000 (95% uncertainty interval:
~44,000–54,000) hospitalisations of rotavirus gastroenteritis and seizures and result in ~50 (95% uncer-
tainty interval: ~25–85) intussusception hospitalisations, over the period 2020–2029 (a benefit-risk ratio
of ~1000:1), compared to a scenario with no public or private sector vaccine use. The discounted vacci-
nation cost would be US$51–57 million over the period 2020–2029 based on per-course prices of US$72
(Rotarix) or US$78 (RotaTeq), but this would be offset by discounted treatment cost savings of US$70
million (government) and US$127 million (governmental and patient health sector). There was a greater
than 94% probability that the vaccine could be cost-saving irrespective of the vaccine product or perspec-
tive considered. All deterministic ‘what-if’ scenarios were cost-saving from an overall health sector per-
spective (governmental and patient).
Conclusions: Rotavirus vaccination is likely to be cost-saving and have a favourable benefit-risk profile in
HK. Based on the assumptions made, our analysis supports its introduction into CIP.
 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Diarrhoea was the fifth leading cause of death in children
younger than 5 years globally in 2016 [1]. Almost 30% of diarrhoea
mortality in this age group was attributable to rotavirus [2]. Rota-
virus gastroenteritis (RVGE) causes significant morbidity in young
children [3,4] and a high economic burden [5] in Hong Kong, a
metropolitan region of approximately 7 million people. An esti-
mated 1 in 33 Hong Kong children are hospitalised for RVGE by
the age of 5 years [4]. There is no compulsory health insurance sys-
tem in Hong Kong. Hong Kong residents can use the government
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they can use the private sector where they will usually pay out-of-
pocket if they do not have their own health insurance. More than
half of inpatient care under 5 years (56.7% in 2016/17) is in the
public sector and needs referral through outpatient or Accident
and Emergency (A&E) services.
There are two licensed rotavirus vaccines available in Hong
Kong. The monovalent vaccine (Rotarix) is a 2-dose rotavirus vac-
cine given at 2 and 4 months of age. The pentavalent vaccine (Rota-
Teq) is a 3-dose rotavirus vaccine given at 2, 4 and 6 months of
age. Rotarix has been shown to be highly efficacious with 96–
97% efficacy in high-income Asian countries including Hong Kong
[6] and both Rotarix and RotaTeq were reported to be safe and
highly efficacious in Europe and the United States in two seminal
clinical studies [7,8]. A recent test-negative case-control study
has confirmed 89–95% effectiveness against rotavirus hospitalisa-
tions in Hong Kong children younger than 5 years [9]. In addition,
rotavirus vaccination has the potential to provide indirect herd
protection to unvaccinated individuals [10] and reduce the risk of
seizures [11–13].
The World Health Organization (WHO) recommends that all
national immunisation programmes include rotavirus vaccines
[14]. Despite rapidly growing evidence of the public health benefits
of rotavirus vaccine and WHO’s recommendation, rotavirus vac-
cine has not yet been included in the Hong Kong Government’s
Childhood Immunisation Programme (CIP). Guardians who would
like their children vaccinated with rotavirus vaccine are required
to take their children to the private sector and pay out-of-pocket.
The private sector price is very high compared to the anticipated
tender price of the vaccine should it be included in the CIP. Unpub-
lished data in 2015 indicated that lower-income families in Hong
Kong are less likely to go to the private sector for rotavirus vacci-
nation than higher-income families. There is no published data
on private sector rotavirus vaccine uptake in Hong Kong. From per-
sonal communication with the Department of Health (DH), 33.3%
of 8723 Hong Kong children born between 2009 and 2012 received
rotavirus vaccines in the private sector. This low uptake rate com-
pares to the immunisation coverage rate of over 95% for vaccines
included in the CIP such as combined Diphtheria-Tetanus-
Pertussis (DTP) vaccines [15].
A previous study published in 2008, using 2002 data, showed
that rotavirus vaccination would be cost-saving to the Hong Kong
Government if the full-course vaccine cost was less than US$40–92
[16]. However, updated evidence is now available for several
inputs and it is possible to calculate additional outcomes, including
the costs that could be saved by households, the number of sei-
zures that could be prevented and the expected ratio of vaccine
benefits (RVGE and seizures hospitalisations prevented) to vaccine
risks (intussusception hospitalisations caused). This study aimed to
evaluate the cost-effectiveness of Rotarix and RotaTeq vaccina-
tion in Hong Kong from both a governmental health sector and
overall health sector (governmental plus patient) perspective, by
comparing each vaccine to a scenario without rotavirus
vaccination.2. Methods
A scenario with rotavirus vaccination (either Rotarix or Rota-
Teq) included in the CIP was compared to a scenario without rota-
virus vaccination. In order to capture the changes in time-
dependent parameters, we evaluated 10 successive annual birth
cohorts from 2020 to 2029, i.e., we calculated the lifetime costs
and benefits associated with vaccinating all 10 birth cohorts. All
monetary costs and effects were discounted at 3% per year, as sug-46gested in the WHO’s guide [17]. All monetary units were adjusted
to 2018 United States dollars (US$).
The primary outcome measure was the discounted cost (US$)
per disability-adjusted life-year (DALY) averted. We also calculated
the ratio of benefits to risks (number of RVGE and seizures hospi-
talisations averted per one intussusception hospitalisation caused)
and other indicators, e.g., numbers of cases, outpatient and A&E
visits, hospitalisations and DALYs prevented, costs of vaccination
and treatment costs averted.
2.1. Model
We used the UNIVAC model (version 1.4), a transparent Excel-
based decision-support model with a universal framework for
evaluating the potential impact and cost-effectiveness of different
vaccines. This is a deterministic static cohort model with a finely
disaggregated age structure (weeks of age between birth and age
5.0 years). The methods used to calculate the potential benefits
and risks of vaccination are described in detail elsewhere [18,19].
UNIVAC was customised to evaluate the protective effect of the
vaccine on community cases, clinic visits and hospitalisations
caused by RVGE. In addition, we evaluated the protective effect
of the vaccine on hospitalisations associated with seizures. We also
evaluated the potential increase in the number of intussusception
hospitalisations (a rare bowel disorder) that could be caused by the
vaccine.
2.2. Model parameters
The model input parameters included: demographics, burden of
disease, vaccine schedule and coverage, vaccine efficacy, vaccine
programme costs, health services utilisation and costs, non-
healthcare costs, vaccine safety and possible vaccine-associated
risks (intussusception), and potential vaccination benefits (sei-
zure). Table 1 lists the estimates and uncertainty ranges of all input
parameters in the model.
2.2.1. Demographic data
The number of live births per year and life expectancy at birth
were obtained from the United Nations World Population Pro-
spects 2017 revision [20].
2.2.2. Burden of disease
2.2.2.1. RVGE. Rotavirus disease burden was estimated from the
event rates of inpatient, outpatient and A&E visits to publicly
funded government clinics/ hospitals (Hospital Authority, HA)
and private sector clinics and hospitals. RVGE requiring hospitali-
sation was classified as severe RVGE. Those with outpatient or
A&E visits only were regarded as non-severe RVGE. To be conserva-
tive from an overall health sector perspective (both governmental
and patient), we assumed no symptomatic RVGE cases treated at
home, i.e., all cases not seen in a health facility were considered
as subclinical. All severe RVGE cases were assumed to have had a
prior outpatient or A&E visit before hospitalisation and we
assumed no death from RVGE given its very low mortality rate in
high-income countries (HICs) [21]. However, we did consider a
very low rate of RVGE mortality in the sensitivity analyses.
We assumed the incidence rate of outpatient and A&E visits for
non-severe RVGE in Hong Kong to be the same as that in Taiwan
before the introduction of rotavirus vaccination (taking the differ-
ence between rates of outpatient/ A&E and hospitalisation) [22],
given Hong Kong and Taiwan are both high-income regions in Asia
and geographically close to each other. The incidence of rotavirus
hospitalisation in children younger than 5 years was obtained from
a previous surveillance study undertaken from 1997 to 2011,
which used adjustment factors derived from laboratory
Table 1
List of parameters, point estimates in base-case analysis and ranges used in probabilistic sensitivity analysis.
Input parametera Point estimate Uncertainty rangeb Source or assumptions
Disease events per 100,000 per year, <5 years, Non-severe RVGE
Community cases 7791 (5728–9851) Assumed that all symptomatic
community cases have access to care
Clinic and A&E visits 7791 (5728–9851) [21]
Disease events per 100,000 per year, <5 years, Severe RVGE
Community cases 1029 (863–1093) –
Clinic and A&E visits 1029 (863–1093) Assumed all severe RVGE cases have a
prior outpatient or A&E visit before
hospitalisation
Hospitalisationsc 1029 (863–1093) [4]
Deaths 0.00 (0.00–0.00) Assumed no rotavirus-associated
deaths
Disease events per 100,000 per year, <5 years, Seizuresd
Community cases 1800 (1418–1980) –
Clinic and A&E visits 1800 (1418–1980) Assumed all seizure cases have a prior
outpatient or A&E visit before
hospitalisation
Hospitalisations 1800 (1418–1980) Derived from local database [4]
Deaths 0.00 (0.00–0.00) Assumed no seizures-associated deaths
Disease events per 100,000 per year, <5 years, Intussusceptione
Community cases 38.00 (34.20–41.80) –
Clinic and A&E visits 38.00 (34.20–41.80) Assumed all intussusception cases have
a prior outpatient or A&E visit before
hospitalisation
Hospitalisations 38.00 (34.20–41.80) [26]
Deaths 0.00 (0.00–0.00) Assumed no intussusception-
associated deaths
Age distribution scale parameterf
RVGE 75.42 (56.56–94.27) [4]
Seizures 558.38 (418.78–697.97) Derived from local database [4]
Intussusception 16.26 (12.19–20.32) Derived from local database [4]
Disability-Adjusted Life Year (DALY) weight
Non-severe RVGE 18.8% (12.5–26.4) [23]
Severe RVGE 24.7% (16.4–34.8) [23]
Seizures 26.3% (17.3–36.7) [23]
Intussusception 32.4% (22.0–44.2) [23]
Mean duration of illness (days)
Non-severe RVGE 3.0 (3.0–3.0) [62]
Severe RVGE 4.0 (3.0–5.0) Assume equivalent to length of hospital
stay [3,4,9,25]
Seizures 3.0 (2.0–4.0) Assumed equivalent to length of
hospital stay (derived from local
database [4])
Intussusception 4.0 (3.0–5.0) Assumed equivalent to length of
hospital stay [27-29]
Vaccine coverage (2020–2029)g
Dose 1 95.0% (90.0–100.0) [14]
Dose 2 95.0% (90.0–100.0) [14]
Dose 3 95.0% (90.0–100.0) [14]
Vaccine timeliness scale parameter (median age in weeks)h
Dose 1 11.37 (8.53–14.21) Data from MCHCs
Dose 2 21.76 (16.32–27.20) Data from MCHCs
Dose 3 34.36 (25.77–42.95) Data from MCHCs
Relative risk of intussusception in the 1–7 day risk period
Dose 1 6.62 (3.91–11.20) Meta-analysis of 7 studies from high-
income countries (refer to Appendices
for details)
Dose 2 2.17 (1.48–3.17) Meta-analysis of 7 studies from high-
income countries (refer to Appendices
for details)
Dose 3 1.00 (1.00–1.00) Assumed no risk
Relative risk of intussusception in the 8–21 day risk period
Dose 1 2.02 (1.13–3.62) Meta-analysis of 7 studies from high-
income countries (refer to Appendices
for details)
Dose 2 1.51 (1.04–2.18) Meta-analysis of 7 studies from high-
income countries (refer to Appendices
for details)
Dose 3 1.00 (1.00–1.00) Assumed no risk
Vaccine efficacy 2 weeks after vaccination, Rotarix, 2 doses
Non-severe RVGEi 75.90% (72.40–86.80) [30]
Severe RVGEj 99.60% (99.40–99.73) [28]
Seizures 29.50% (21.00–38.00) [12,31]
(continued on next page)
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Table 1 (continued)
Input parametera Point estimate Uncertainty rangeb Source or assumptions
Vaccine efficacy 2 weeks after vaccination, Rotarix, 1 dose
Non-severe RVGE 68.31% (65.16–78.12) Assumed same proportion of full-
course efficacy as severe RVGE
Severe RVGE 89.64% (89.46–89.75) [29]
Seizures 26.55% (18.90–34.20) Assumed same proportion of full-
course efficacy as severe RVGE
Vaccine efficacy 2 weeks after vaccination, RotaTeq, 3 doses
Non-severe RVGEi 75.90% (72.40–86.80) [30]
Severe RVGEj 99.60% (99.40–99.73) [28]
Seizures 29.50% (21.00–38.00) [12,31]
Vaccine efficacy 2 weeks after vaccination, RotaTeq, 2 doses
Non-severe RVGE 65.27% (62.26–74.65) Assumed same proportion of full-
course efficacy as severe RVGE
Severe RVGE 85.65% (85.48–85.77) [29]
Seizures 25.37% (18.06–32.68) Assumed same proportion of full-
course efficacy as severe RVGE
Vaccine efficacy 2 weeks after vaccination, RotaTeq, 1 dose
Non-severe RVGE 63.76% (60.82–72.91) Assumed same proportion of full-
course efficacy as severe RVGE
Severe RVGE 83.66% (83.50–83.77) [29]
Seizures 24.78% (17.64–31.92) Assumed same proportion of full-
course efficacy as severe RVGE
Mean duration of protection (months), 1, 2 or 3 doses j
Non-severe RVGE 176.80 (114.70–268.0) Assumed to be the same as severe RVGE
Severe RVGE 176.80 (114.70–268.0) [28]
Seizures 176.80 (114.70–268.0) Assumed to be the same as severe RVGE
Vaccination costs, Rotarix
Price per dose 36.00 (31.00–46.00) From PCV experience and
manufacturers
Incremental cost to the health
system per dose (2020–2029)
3.29 (Extra manpower cost: 3;
Annualised capital cost of refrigerators
and recurrent maintenance cost: 0.29)
(2.46–4.11) Finance Department of a HA hospital
and company selling refrigerators
Vaccination costs, RotaTeq
Price per dose 26.00 (23.00–34.00) From PCV experience and
manufacturers
Incremental cost to the health
system per dose (2020–2029)
3.19 (Extra manpower cost: 3;
Annualised capital cost of refrigerators
and recurrent maintenance cost: 0.19)
(2.39–3.99) Finance Department of a HA hospital
and company selling refrigerators
Mean cost per clinic and A&E visit (Governmental health sector perspective)k
Non-severe RVGE 9.00 (7.00–11.00) Refer to Appendices for details
Severe RVGE 83.00 (62.00–103.00)
Seizures 83.00 (62.00–103.00)
Intussusception 83.00 (62.00–103.00)
Mean cost per clinic and A&E visit (Governmental and patient health sector perspective)k Refer to Appendices for details
Non-severe RVGE 56.00 (42.00–70.00)
Severe RVGE 171.00 (128.00–213.00)
Seizures 171.00 (128.00–213.00)
Intussusception 171.00 (128.00–213.00)
Mean cost per hospitalisation (Governmental health sector perspective) Refer to Appendices for details
Severe RVGE 1702.00 (1277.00–2128.00)
Intussusception 1748.00 (1320.00–2176.00)
Seizures 1277.00 (851.00–1702.00)
Mean cost per hospitalisation (Governmental and patient health sector perspective) Refer to Appendices for details
Severe RVGE 2888.00 (2166.00–3611.00)
Seizures 2164.00 (1443.00–2885.00)
Intussusception 3317.00 (2593.00–4041.00)
A&E, Accident and Emergency; HA, Hospital Authority; MCHC, Maternal and Child Health Centre; PCV, pneumococcal conjugate vaccine; PSA, probabilistic sensitivity
analysis; RVGE, rotavirus gastroenteritis.
a All costs are in 2018 United States dollars.
b For each probabilistic simulation, parameters were drawn from a distribution with a mean equal to the point estimate and range equal to the low and high values of the
uncertainty range. A PERT-Beta distribution was assumed for all parameters [45].
c The three adjusted incidence rates in the previous local study were taken as base-case estimate and uncertainty range.
d Base-case estimate was derived from local database with any Clinical Management System seizure diagnosis in any diagnostic position over 14-year period (1997–2011),
the low value of the uncertainty range in PSA was derived using seizure cases as primary diagnoses only, and the high value was + 10% of the base-case estimate.
e Base-case estimate was varied by ±10% in PSA.
f All age distributions were fitted to a three-parameter Burr distribution using non-linear least squares minimisation [22]. The scale parameter was varied by ±25% in PSA.
Other parameters were fixed for rotavirus (shape 1 = 1.76, shape 2 = 1.07), intussusception (shape 1 = 4.83, shape 2 = 0.14) and seizures (shape 1 = 1.69, shape 2 = 10.47).
g Base-case estimate was varied by ±5 percent-points in PSA.
h The timeliness of vaccination (coverage by week of age) was fitted to a two-parameter Log Logistic distribution using non-linear least squares minimisation. The scale
parameter (median age in weeks) was varied by ±25% in PSA. The shape parameter was fixed for dose 1 (18.05), dose 2 (21.01) and dose 3 (13.14).
i The reported estimate from developed countries on effectiveness 86.8% (95% CI: 60.7–95.6) was taken as the high value of the uncertainty range, and the reported efficacy
75.9% (95% CI: 72.4–78.9) was taken as the base-case estimate and its lower bound of the 95% CI was taken as the low value of the uncertainty range in PSA.
j A two-parameter cumulative gamma distribution was used to estimate vaccine efficacy against severe RVGE by duration of follow-up. The parameters were based on the
median and 95% credible intervals generated by a Bayesian meta-regression of all randomised trials in high-income settings [28]. The same duration of protection was
assumed for non-severe RVGE and seizures. The alpha parameter (0.93) was fixed in PSA.
k Base-case estimate was varied by ±25% in PSA.
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discharge diagnosis information (Clinical Management System,
CMS) from all HA hospitals to compensate for under-reporting,
with estimates made for private hospital admissions [4]. Despite
the availability of rotavirus vaccines in the private sector since
2006, there was no reduction in the incidence of hospitalisation
for either rotavirus or all-cause gastroenteritis observed in Hong
Kong children younger than 5 years over the 14 rotavirus seasons.
Therefore, we assumed that the admission rates from 1997 to 2011
were reflective to ‘no vaccination’ despite the availability of vac-
cine in the private sector since 2006.
The age distribution of RVGE cases was estimated from that of
RVGE hospitalisation [4] which was fitted with a Burr distribution
using non-linear least squares minimisation [23]. The disability
weights for DALYs were taken from the Global Burden of Disease
study [24]. The gastrointestinal symptoms of a RVGE patient gen-
erally resolve in 3–7 days [25]. We assumed the duration of illness
of non-severe RVGE be the minimum of this range. The length of
hospital stay for severe RVGE was estimated to be 4 days [4] (3
[3,4,9] – 5 [4,26]). Assuming no recovery period, the duration of ill-
ness of severe RVGE was assumed to be equal to the length of hos-
pital stay.
2.2.2.2. Seizures. All seizure cases were assumed to be hospitalised
with a prior outpatient or A&E visit. Using HA data from 1997 to
2011, as in the study by Chiang et al. [4] and the same methodol-
ogy, the unadjusted incidence rate of hospitalisation for seizures in
public hospitals, of children younger than 5 years, was estimated to
be 1800 per 100,000 person-years as a reasonable estimate of pre-
vaccination incidence. The mortality rate from seizures was
assumed to be 0. From the same database [4], among children
younger than 5 years, 15.7% was younger than 1 year and 84.3%
was aged from 1 to 5 years, and the median length of hospital stay
for seizures was 4 days for infants and 3 days for children aged
from 1 to 5 years. The weighted median length of hospital stay
(3 days) was taken as the base-case estimate, with an uncertainty
range of 2–4 days. Assuming no recovery period, duration of illness
for seizures was assumed to be the length of hospital stay. The dis-
ability weight for DALYs was estimated at 0.263 (95% CI: 0.173,
0.367) [24].
2.2.2.3. Intussusception. All intussusception cases were assumed to
be hospitalised with a prior outpatient or A&E visit. The hospitali-
sation rate of intussusception in children younger than 5 years was
estimated to be 38 per 100,000 person-years [27]. We calculated
the number of expected vaccine-related hospitalisations following
introduction of the vaccine. We did not calculate the number of
vaccine-related intussusception deaths because intussusception
is a very rare event and case-fatality ratios (CFRs) have been esti-
mated to be very low locally and in high-income settings [18,27].
However, we did consider a very low rate of intussusception mor-
tality in the sensitivity analysis.
A local study reported that intussusception surgical rate was
26.5% and the median length of post-reduction hospital stay for
non-surgical patients was 3 days and 7.5 days for surgical patients
[28]. Assuming no recovery period, duration of illness was
assumed to be the weighted average of length of hospital stay.
The disability weight for DALYs was estimated at 0.324 (95% CI:
0.220, 0.442) [24].
2.2.3. Vaccine schedule and coverage
Coverage of rotavirus vaccination after introduction was
assumed to be the current coverage for vaccines included in the
CIP (95%) for all doses of vaccination over the 10 successive annual
birth cohort since vaccines included in the routine universal CIP
rapidly attain high coverage as shown following the introduction49of pneumococcal conjugate vaccine (PCV) [15]. Data on the timeli-
ness (coverage by week of age) of DTP vaccination was obtained
from the Maternal and Child Health Centre (MCHC) based on a
birth cohort born in 2011. The observed timeliness data was fitted
with a two-parameter Log Logistic distribution using non-linear
least squares minimisation. Combining data on coverage by week
of age with estimates of disease burden by week of age allowed
for more precise estimates of the potential direct effects of
vaccination.
2.2.4. Vaccine efficacy
2.2.4.1. RVGE. Estimates of vaccine efficacy by duration of follow-
up were taken from a recent meta-analysis of randomised con-
trolled trials in settings with low under-five mortality [29]. We
used the pooled estimates (and 95% credibility intervals) of vaccine
efficacy against severe RVGE after a full course of either Rotarix or
RotaTeq. Efficacy of one dose of Rotarix was estimated to be 90%
of the efficacy value estimated for 2 doses (full-course) [30]. For
RotaTeq, one-dose and two-dose vaccine efficacy were assumed
to be 84% and 86% of the efficacy value estimated for 3 doses
(full-course) [30]. The duration of vaccine efficacy was obtained
from the same meta-analysis [29] and all doses were assumed to
have the same duration of vaccine efficacy.
Vaccine efficacy against non-severe RVGE was estimated to be
75.9% based on the efficacy of rotavirus vaccination in preventing
rotavirus diarrhoea of any severity in developed countries [31].
2.2.4.2. Seizures. A full course of rotavirus vaccination was shown
to reduce the risks of seizure-associated hospitalisation or emer-
gency care by 21% in the United States [12] and to have vaccine
efficacy of 38% against hospitalisation [32]. These percentages
were used as the uncertainty range of vaccine efficacy against sei-
zures and the average of this range was taken as the base-case esti-
mate. However, there is also a study showing no significant
association between rotavirus vaccine introduction and seizure
admission [33]. A sensitivity analysis was conducted in the absence
of this potential benefit.
2.2.5. Intussusception
Both Rotarix and RotaTeq have been associated with an ele-
vated risk of a rare bowel disorder (intussusception) in some set-
tings [34,35]. We estimated the expected number of
intussusception hospitalisations that could be caused by the vac-
cine as well as the costs of treating these cases.
The overall background intussusception rates for Hong Kong
children younger than 1 and 5 years were previously reported to
be 108 and 38 per 100,000 children respectively [27]. A meta-
analysis has been performed on the relative risk of intussusception
within different periods post rotavirus vaccination in HICs. Among
the six studies included, three studies reported for Rotarix
[34,36,37], one study for RotaTeq [38] and two studies for both
vaccines [35,38]. Appendix Fig. 1 illustrates the relative risks of
intussusception within 1–7 days and 8–21 days after first and sec-
ond doses of rotavirus vaccine.
2.2.6. Vaccine programme costs
Potential tender prices of Rotarix and RotaTeq were requested
and received from the manufacturers. We used a ‘symbolic’ price of
US$92 (US$46 per dose) for a full course of Rotarix as suggested by
the manufacturer, where the price was based on the upper bound
of the cost-neutral vaccine cost (i.e., the price at which the vaccine
would be cost-saving from a governmental perspective) of a previ-
ous study by Ho et al., 2008 [16], and a private market price of
RotaTeq in Hong Kong of US$34 per dose (US$102 per course) pro-
vided by the manufacturer. These were taken as the upper bound
of the uncertainty range. The vaccine price in the base-case analy-
Karene Hoi Ting Yeung, Shi Lin Lin, A. Clark et al. Vaccine 39 (2021) 45–58sis was based on the experience of PCV in Hong Kong. The percent-
age reduction in the tender price from the market price was
obtained by using the market price used in two previous economic
analyses of PCV before its introduction in Hong Kong (US$65 per
dose) [39,40] and the 2019 tender price of PCV (US$50.7 per dose);
this was 22%. An additional 10 percentage-points of reduction was
taken as the lower bound of the uncertainty range. The per-course
prices of Rotarix and RotaTeq were estimated to be US$72 (US$36
per dose) and US$78 (US$26 per dose) respectively in the base case
and US$62 (US$31 per dose) and US$69 (US$23 per dose) in the
lower bound of the uncertainty range. No additional cost for inter-
national handling and delivery and vaccine wastage were assumed
in the base case but 5% of vaccine wastage was considered as the
upper bound of the uncertainty range.
Extra time cost for MCHC nurses to explain and administer one
rotavirus vaccine dose was estimated to be US$3 for 5 min, based
on the nominal annual mid-point salary for a registered nurse in
2018/19 from the Finance Department of Prince of Wales Hospital.
We assumed no additional costs for extra staff, advertising, invita-
tion letter, phone call, surveillance and monitoring or indirect costs
of the vaccination programme such as loss of productivity of care-
givers since rotavirus vaccination could be fitted into the existing
schedule of childhood vaccination. We also assumed no additional
cost incurred from vaccination side effects except intussusception.
The model of refrigerators being used in the MCHCs was
obtained from the DH. The rotavirus vaccine storage volume
required was calculated using a WHO guidance document [41]. It
was estimated that one additional refrigerator would be installed
for rotavirus vaccine storage for each of the 31 MCHCs. A quotation
for the refrigerator was obtained and its cost was annualised with a
10-year expected useful lifetime. We also estimated the recurrent
maintenance cost of refrigerators to be 10% of its cost.
2.2.7. Health services utilisation and costs
Among children younger than 5 years, the proportion of
patients using health services from public or private sectors are
56.7% and 43.3% respectively for inpatient and 16.3% and 83.7%
respectively for outpatient services [42]. For patients with mild ill-
ness using public services, 90.9% would go to an outpatient clinic
and 9.1% to A&E [43]. For hospitalised RVGE patients in the public
sector, 16.7% would have had a prior visit at the government out-
patient clinic and 83.3% had a prior A&E visit (unpublished data
[5]). Fig. 1 shows a flowchart of health service usage for RVGE in
Hong Kong. To provide conservative results, we assumed there
were no private A&E and traditional Chinese medicine
consultations.
Health service costs were calculated for non-severe RVGE (out-
patient and A&E visits) and for severe RVGE (outpatient and A&E
visits and inpatient). From the governmental health sector per-
spective, costs were calculated as the cost to the Government
(HA or DH) subtracting the cost paid by the patient to the Govern-
ment, which was then multiplied by the percentage using the pub-
lic service. From the overall health sector perspective (both
governmental and patient), costs were calculated as the weighted
average of cost to the Government plus cost to patients using the
private service. Average cost for hospitalisation was calculated as
cost per patient day multiplied by length of hospital stay in days.
Health service utilisation for intussusception and seizures was
assumed to be the same as that of severe RVGE. Table 1 lists the
cost inputs in the model and detailed calculations of health service
costs are shown in the Appendix Tables 1–6.
2.2.8. Non-healthcare costs
To provide conservative results, only costs of transportation and
additional diapers for RVGE children were considered in the model.
Other miscellaneous costs such as food supplements or non-50prescription remedies and indirect costs such as loss of productiv-
ity of parents or other caregivers were not considered.
Transportation costs for a sick child and an accompanying care-
giver for an outpatient or A&E visit in public and private sectors
were estimated. A round-trip travel cost by taxi was assumed to
be US$13 by estimating a round-trip distance of 5 km between
home and a health service facility. No additional travel cost was
assumed from outpatient clinics to hospitals.
An additional two diapers per day was estimated to be required
for each RVGE child aged from 0 to 3 years [44]. The cost per diaper
was estimated to be US$0.39 (obtained from the Consumer Coun-
cil). The cost of additional diapers was the product of additional
daily cost and duration of illness in days. Given the cumulative pro-
portion of RVGE cases aged from 0 to 3 years was 87% [4], the addi-
tional daily cost was estimated at US$0.65 per case.
2.3. Model analyses
2.3.1. Cost-effectiveness analysis
For each vaccine product, we calculated the discounted cost per
DALY averted compared to no vaccination:
Incremental costs of including rotav irus vaccination into CIP
Costs averted by rotav irus vaccine
DALYs averted by rotav irus vaccine
A negative value of the numerator indicates introduction of
rotavirus vaccine is cost-saving. Hong Kong does not have an
accepted willingness-to-pay threshold [45] but in the previous
study a discounted cost per DALY averted of less than one times
Gross Domestic Product (GDP) per capita was considered to be
cost-effective [16].
2.3.2. Cost-benefit analysis
We did not convert DALYs averted into monetary values, as this
process is often controversial and based on uncertain assumptions.
However, we did calculate the proportion of probabilistic simula-
tions that led to a cost-saving result.
2.3.3. Probabilistic sensitivity analyses
Probabilistic sensitivity analyses were conducted to quantify
the level of confidence in the output, in relation to the uncertainty
in the model inputs; 1000 probabilistic simulations were run for
each vaccine. For each probabilistic simulation, parameters were
drawn from a distribution with a mean equal to the point estimate
and range equal to the low and high values of the uncertainty
range. For simplicity, a PERT-Beta distribution was assumed for
all parameters [46]. A benefit-risk ratio for hospitalisation was cal-
culated for each simulation by dividing the number of RVGE and
seizure hospitalisations prevented by the number of intussuscep-
tion hospitalisations.
2.3.4. Deterministic scenario analyses
A series of deterministic scenario analyses were conducted to
evaluate the impact of different input parameters on the results.
We ran one-way scenarios based on the low and high values of
the uncertainty range of each input parameter, and multi-way sce-
narios with several inputs were varied at the same time to gener-
ate favourable and unfavourable scenarios for rotavirus vaccine
introduction. All scenarios are listed in Table 2.
2.4. Ethics approval
Ethics approval was granted by the Joint Chinese University of
Hong Kong – New Territories East Cluster Clinical Research Ethics
Committee (Ref.: CRE-2016.717).
Fig. 1. Flowchart of health service usage for rotavirus gastroenteritis in Hong Kong. a[41]. b[42]. c[3]. dOverall 56.7% and 43.3% [41] admitted to public and private hospitals
respectively. A&E, Accident and Emergency; GOPC, general outpatient clinic; GP, general practice clinic; RVGE, rotavirus gastroenteritis For both non-severe and severe RVGE,
we multiplied the total number of visits (outpatient visits and A&E visits) by the average cost per visit, calculated by taking into account whether visits were in outpatient
clinics or A&E departments, whether visits were public or private and the costs and probabilities associated with each. For the average cost per severe RVGE hospitalisation,
we multiplied the length of hospital stay in days by the cost per day. The average costs per visit and per hospitalisation were calculated separately for both of the perspectives
considered. Detailed calculations can be found in the Appendices.
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3.1. Cost-effectiveness
From the base-case scenario, over the period of 2020 to 2029,
the discounted costs of rotavirus vaccination would be US$51 mil-
lion and US$57 million based on per-course prices of US$72
(Rotarix) or US$78 (RotaTeq), but this would be offset by dis-
counted treatment cost savings of US$70 million to the Hong Kong
Government and US$127 million to both the government and
patient, making the introduction of rotavirus vaccine into the Hong
Kong CIP a cost-saving intervention. With rotavirus vaccination in
the CIP, US$13–20 million and US$70–77 million could be saved
from the governmental alone and the governmental plus patient
health sector perspectives respectively over a 10-year period.3.2. Health impacts
We estimated in the base-case scenario that there could be
190,000 non-severe and 33,000 severe RVGE cases prevented by
rotavirus vaccination in Hong Kong over the period 2020–2029
(Table 3). In addition, we estimated that 17,000 seizures could be
prevented and that 47 additional cases of rotavirus vaccine-
associated intussusception could be caused. The total numbers of
outpatient and A&E visits and hospitalisations with and without
rotavirus vaccine over the 10-year period are shown in Fig. 2. Over
the 10-year period, around 350 DALYs could be averted by rota-
virus vaccination (Table 3).3.3. Probabilistic sensitivity analyses
The probabilistic sensitivity analyses showed that there was
100% probability that the two rotavirus vaccines were cost-51saving from the overall health sector perspective (governmental
plus patient), when each were independently compared to no vac-
cination. From the governmental health sector perspective,
Rotarix was 99.2% and RotaTeq was 93.5% likely to be cost-
saving. 100% of the runs had a cost-effectiveness ratio that was
lower than the GDP per capita in Hong Kong in 2018 (US$48,717
[47]). Figs. 3a and 3b show the discounted incremental cost (costs
of vaccination programme less costs averted by vaccine) and
DALYs averted by universal rotavirus vaccination of the 1000 prob-
abilistic simulations.3.4. Benefit-risk analyses
We estimate that rotavirus vaccination could prevent 49,000
(95% uncertainty interval [UI]: ~44,000–54,000) RVGE and seizure
hospitalisations and cause ~50 (95% UI: ~25–85) intussusception
hospitalisations over the period of 2020–2029. This results in a
benefit-risk ratio of ~1000:1 (95% UI: ~550–2000:1).3.5. Deterministic scenario analyses
40 scenarios were evaluated for each vaccine and for govern-
mental alone and overall health sector (governmental plus patient)
perspectives, including best-case and worst-case scenarios. For
Rotarix, all scenarios were cost-saving except the worst-case sce-
nario from both governmental alone and the overall health sector
(governmental plus patient) perspectives. For RotaTeq, the
worst-case scenario was not cost-saving from both governmental
alone and the overall health sector (governmental plus patient)
perspectives, and scenarios with high vaccine price and low costs
of health services were also not cost-saving to the Government.
Since most of the scenarios were cost-saving, the tornado dia-
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52(costs of vaccination programme less costs averted by vaccine),
instead of the discounted cost per DALY averted, of rotavirus vac-
cination introduction for each vaccine and for both governmental
alone and overall health sector (governmental plus patient) per-
spectives. The amount of costs saved by universal vaccination
was most influential by the RVGE healthcare cost; and DALYs
averted was the most influential by the disability weights for
RVGE. The highest combination of DALYs averted and costs saved
was found in the scenario with high disease event rates for RVGE.4. Discussion
This analysis provides a timely update and an expanded per-
spective to a previous study published in 2008 [16] showing that
rotavirus vaccination would likely be cost-saving from both a gov-
ernmental alone and combined governmental and patient health
sector perspective. Deterministic scenario analyses also confirmed
the previous findings that healthcare costs and vaccine price are
the most strongly influential on the amount of costs saved. Proba-
bilistic sensitivity analyses additionally confirmed that both vacci-
nes would have a high probability of being cost-saving when
independently compared to no vaccination. We assumed that both
vaccines would generate similar health benefits and risks. Thus, we
assumed the product with the lowest negotiated price per course
will ultimately be the dominant/ preferred product. We assumed
a per-course price of US$72–78, after applying the same discount
of market price from the experience of PCV in Hong Kong. How-
ever, several new rotavirus vaccines have recently been licensed
for global use, including much cheaper Indian vaccines (ROTAVAC
and ROTASIIL) [48,49]. Several other rotavirus vaccines are also in
the pipeline, including injectable vaccines [48]. Therefore, an even
better reduction in tender price obtained by the Government might
be expected.
Our analysis also suggested that the benefits of rotavirus vac-
cine introduction are likely to far outweigh any potential increases
of intussusception. Approximately 700 RVGE and 300 seizures hos-
pitalisations could be prevented for each extra intussusception
hospitalisation caused. The benefit-risk ratio on RVGE hospitalisa-
tion versus intussusception hospitalisation in Hong Kong is higher
than 6 out of 7 low-mortality countries (190–571:1) [34,35,50–54]
with the United States having a higher ratio (1093:1) [55].
The cost-saving results from the overall health sector perspec-
tive (governmental plus patient) are in line with other prospective
cost-effectiveness studies in HICs in the same region [22,56,57].
However, one study from South Korea which also used the UNIVAC
model showed rotavirus vaccine introduction is cost-effective,
rather than cost-saving, from the societal perspective [58]. This
could be because of the difference in the estimate of vaccine price
used in our models and that protection from seizures was not
included in the South Korea analysis. Vaccine prices, which were
reported as being ‘confidential’ in the South Korean study, could
vary a lot among countries and influence the results since vaccine
price is one of the main drivers of the analysis. From the govern-
mental health sector perspective, prospective cost-effectiveness
studies in Australia [56] and Japan [57] showed cost-effective
results, but a retrospective economic evaluation of the Australian
rotavirus vaccination programme showed cost-saving results for
a full-course rotavirus vaccine at AUS99.52 (~US$84.84) in 2008
over 6 years after the implementation of the programme [59].
Introduction of rotavirus vaccine in Hong Kong, a high-income
region, would have different economic impacts compared to low-
income countries (LICs) and lower-middle-income countries
(LMICs). A systematic review [60] showed that rotavirus vaccine
introduction would be cost-effective or highly cost-effective in
most of these LICs and LMICs. Preventing rotavirus mortality is
Table 3
Health and economic impacts under base-case scenario (10 cohorts vaccinated over the period of 2020–2029).*
Rotarix RotaTeq
No vaccine With vaccine Averted No vaccine With vaccine Averted
Total cases # 412,332 172,755 239,577 412,332 174,771 237,561
Non-severe RVGE 301,414 111,538 189,876 301,414 113,340 188,075
Severe RVGE 39,809 6,901 32,908 39,809 7,214 32,596
Seizures 69,638 52,799 16,839 69,638 52,701 16,937
Intussusception 1,470 1,517  47 1,470 1,517  47
Total outpatient and A&E visits 412,332 172,755 239,577 412,332 174,771 237,561
Non-severe RVGE 301,414 111,538 189,876 301,414 113,340 188,075
Severe RVGE 39,809 6,901 32,908 39,809 7,214 32,596
Seizures 69,638 52,799 16,839 69,638 52,701 16,937
Intussusception 1,470 1,517  47 1,470 1,517  47
Total hospitalisations 110,917 61,217 49,700 110,917 61,431 49,486
Severe RVGE 39,809 6,901 32,908 39,809 7,214 32,596
Seizures 69,638 52,799 16,839 69,638 52,701 16,937
Intussusception 1,470 1,517  47 1,470 1,517  47
DALYs 616 260 356 616 263 353
Total governmental healthcare and non-healthcare costs ^ 144,525,144 73,796,558 70,728,586 144,525,144 74,228,014 70,297,130
Total outpatient and A&E visit costs^ 10,075,603 5,116,851 4,958,752 10,075,603 5,149,793 4,925,810
Total hospitalisation costs^ 134,449,541 68,679,707 65,769,834 134,449,541 69,078,221 65,371,320
Total governmental and patient healthcare and non-healthcare costs^ 258,804,713 130,972,297 127,832,416 258,804,713 131,779,187 127,025,527
Total outpatient and A&E visit costs^ 30,387,629 14,100,651 16,286,978 30,387,629 14,231,121 16,156,508
Total hospitalisation costs^ 228,417,084 116,871,646 111,545,438 228,417,084 117,548,065 110,869,019
Vaccine programme costs^ 51,074,141 56,921,915
A&E, Accident and Emergency; DALYs, disability-adjusted life-years; RVGE, rotavirus gastroenteritis.
* Any estimates of a difference in impact of the two vaccine products should be interpreted with caution as they reflect our uncertain assumptions about the dose-specific
efficacy and waning associated with each product.
# Assumed no symptomatic RVGE cases treated at home.
^ All costs are discounted and in 2018 United States dollars.
Fig. 2. Numbers of outpatient and A&E visits and hospitalisations with and without rotavirus vaccine over the first 10 years of introduction. A&E, Accident & Emergency.
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in LICs and LMICs but as in Hong Kong vaccine price and vaccine
efficacy are also very influential on the cost saved in these
countries.
We considered the potential protection from seizures in our
economic evaluation since this impact has been observed in the
United States, Australia, Spain and England [11–13,32,61]. Since
the burden of seizures in children younger than 5 years is not
low in Hong Kong, 27% of treatment cost savings would be attrib-
uted to the protection from seizures, and 8% of DALYs averted53would be due to prevention of seizures. Considering this protection
in the model will provide the Government with a more compre-
hensive perspective when evaluating the potential impact of rota-
virus vaccine introduction. However one study from England
examining shorter pre- and post-vaccination time periods has
shown no significant association between rotavirus vaccination
and seizure hospitalisations [33], and there is no data in Hong Kong
showing a reduction in seizure incidence. A sensitivity analysis was
also conducted without the consideration of the protection from
seizures. Both products would still be 100% cost-saving to the
Fig. 3a. Discounted incremental costs versus disability-adjusted life-years (DALYs) averted from a probabilistic sensitivity analysis for monovalent rotavirus vaccine
(Rotarix).
Fig. 3b. Discounted incremental costs versus disability-adjusted life-years (DALYs) averted from a probabilistic sensitivity analysis for pentavalent rotavirus vaccine
(RotaTeq).
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40% likely to be cost-saving to the Government alone. This lower
probability compares to the 94–99% probability when the protec-
tion from seizures is included. Excluding the potential protection
from seizures, the full-course vaccine prices leading to cost-
saving results to the Government are close to that estimated from
the previous economic evaluation in Hong Kong [16].
The two vaccine products evaluated in this analysis have not
been compared head-to-head in a randomised controlled trial,
and there is limited evidence to suggest a meaningful difference
in real-world impact or safety when both vaccines have been used
concurrently in the same country [62,63]. For this reason, we did54not calculate the incremental cost-effectiveness of one product
compared to the other, and instead present the cost-effectiveness
of each vaccine compared to no vaccination. In addition, any esti-
mates of a difference in impact should be interpreted with caution
as they reflect our uncertain assumptions about the dose-specific
efficacy and waning associated with each product.
A PERT-Beta distribution was assumed for all parameters in the
probabilistic sensitivity analyses. It is a flexible distribution that
can be easily incorporated into decision-support models where
there is uncertainty about the shape of the distribution and what
the appropriate range should be. We acknowledge that it is a sim-
plified approach with skewing and smoothing on the basis of the
Fig. 4a. Tornado diagram for monovalent rotavirus vaccine (Rotarix) introduction in terms of discounted incremental cost to the government from deterministic scenario
analyses (discounted incremental cost in the base-case analysis = US$19.654 million). A&E, Accident and Emergency; RVGE, rotavirus gastroenteritis.
Fig. 4b. Tornado diagram for monovalent rotavirus vaccine (Rotarix) introduction in terms of discounted incremental cost to the society from an overall health sector
perspective (governmental and patient) from deterministic scenario analyses (discounted incremental cost in the base-case analysis = US$76.758 million). A&E, Accident
and Emergency; RVGE, rotavirus gastroenteritis.
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could have been used to improve the probabilistic sensitivity anal-
yses but this would require more data than was available, and we
do not believe this would alter the main conclusions or recommen-
dations of the analyses.
UNIVAC is a deterministic static cohort model that can be used
to generate estimates of the direct effects of vaccination. Indirect
vaccine benefits such as herd protection, cross-protection against
non-vaccine rotavirus genotypes and reduction of nosocomial
infections were not considered in this analysis, so estimates should
be regarded as conservative. Developing and calibrating a trans-
mission dynamic model to the Hong Kong context would be an
option to account for the indirect vaccine benefit [64] but this
would be difficult to justify given the favourable cost-55effectiveness and benefit-risk results based on the direct effects
of vaccination alone. A scenario with very high vaccine efficacy
(scenario 13) provides an indication of the potential impact of herd
effects on the results. However, given the high coverage and high
efficacy of vaccines in Hong Kong, the indirect benefits are antici-
pated to be minimal once the vaccine has been introduced for sev-
eral years, and all birth cohorts younger than 5 years are
participating in the programme.
Also, we used the estimates of RVGE hospitalisation incidence
from 1997 to 2011 [4], where rotavirus vaccine has been available
in the private market since 2006. This data reflects the rotavirus
disease burden before increased uptake of the vaccine in the pri-
vate sector. We assumed no vaccination during the period of
2006–2011 in the private sector as no reduction in the incidence
Fig. 4c. Tornado diagram for pentavalent rotavirus vaccine (RotaTeq) introduction in terms of discounted incremental cost to the government from deterministic scenario
analyses (discounted incremental cost in the base-case analysis = US$13.375 million). A&E, Accident and Emergency; RVGE, rotavirus gastroenteritis.
Fig. 4d. Tornado diagram for pentavalent rotavirus vaccine (RotaTeq) introduction in terms of discounted incremental cost to the society from an overall health sector
perspective (governmental and patient) from deterministic scenario analyses (discounted incremental cost in the base-case analysis =US$70.104 million) A&E, Accident and
Emergency; RVGE, rotavirus gastroenteritis.
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was observed in Hong Kong children younger than 5 years over
the 14 rotavirus seasons. However, the impact of 49,000 RVGE
and seizure hospitalisations prevented should be interpreted with
caution as this reflects our uncertain assumption about the base-
line burden. A sensitivity analysis was conducted with the best
estimate of pre-vaccination RVGE hospitalisation incidence, using
the surveillance data from 2001 to 2003 based on the WHO Gen-
eric Protocol [3,4]. By estimating the RVGE hospitalisation to be
845 (810–880) per 100,000 person-years, rotavirus vaccination
would still be 100% cost-saving to the society from an overall
health sector perspective and <94% cost-saving to the Government;
and there would be 43,000 (95% UI: 40,000–47,000) RVGE and sei-
zure hospitalisations prevented.56In addition, we were conservative when making assumptions
on the input parameters. We assumed no traditional Chinese med-
icine consultations, miscellaneous costs and loss of productivity of
caregivers associated with RVGE. We also assumed no costs for
mild RVGE cases treated at home which would result in a more
conservative estimate from an overall health sector perspective.
We assumed no death from and no private A&E consultation for
both RVGE and intussusception, providing an overall conservative
estimate due to the higher burden of RVGE than intussusception.
Mortality from either RVGE or intussusception is very rare in Hong
Kong, so excluding deaths from both diseases from our analyses
would not alter the conclusions of our analysis. Had we applied
our known but highly uncertain (due to small numbers of deaths)
CFRs for RVGE and intussusception [18,27], there would have been
Karene Hoi Ting Yeung, Shi Lin Lin, A. Clark et al. Vaccine 39 (2021) 45–58<10 RVGE deaths prevented, and no intussusception deaths caused
over the 10-year period of the analysis.
We estimated the disability weights for DALYs from the Global
Burden of Disease study [24]. Rather than using DALYs to estimate
the quality of life for each episode of RVGE, we could have used
quality-adjusted life years (QALYs) based on detailed question-
naires administered to individuals in Hong Kong. However, since
treatment cost savings outweighed vaccination costs in most of
our probabilistic simulations, the choice of using QALYs versus
DALYs would not be influential to the outcome, i.e., that the vac-
cine is likely to be cost-saving in Hong Kong.
As revealed by the deterministic scenario analyses, the highest
combination of costs saved and DALYs averted is the scenario with
high disease event rates of RVGE. We believe that our findings will
be of interest to HICs that have not yet introduced rotavirus vac-
cine and have a high disease burden of rotavirus in terms of rates
of hospitalisation, as seen in Hong Kong.
In conclusion, rotavirus vaccine, which has been shown to be
effective in preventing RVGE and reducing morbidity, is likely to
be cost-saving to the Hong Kong Government and payers. Its incor-
poration into the CIP would reduce the burden of disease of RVGE
and the associated healthcare and non-healthcare costs and would
provide more equitable healthcare access to the community. This
economic evaluation can guide policy makers to formulate
informed decisions on whether to incorporate rotavirus vaccine
into the CIP.
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